Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs
Start-Up Has Raised Nearly $775m To Date
Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.
